Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | PDE4A | P27815 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.63 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.63 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.56 |
| ▸ | RARB | P10826 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14125946 | 1.00 | PLA2G4B (0.63) | PLA2G4BKDM4ECYP1A2CYP2D6PDE4A | |
| SCHEMBL31473503 | 1.00 | PLA2G4B (0.63) | PLA2G4BKDM4ECYP1A2CYP2D6PDE4A | |
| SCHEMBL10757136 | 1.00 | PLA2G4B (0.63) | PLA2G4BKDM4ECYP1A2CYP2D6PDE4A | |
| SCHEMBL9160866 | 1.00 | PLA2G4B (0.63) | PLA2G4BKDM4ECYP1A2CYP2D6PDE4A | |
| SCHEMBL7280156 | 1.00 | PLA2G4B (0.63) | PLA2G4BKDM4ECYP1A2CYP2D6PDE4A | |
| SCHEMBL3333378 | 0.95 | KDM4E (0.69) | PLA2G4BKDM4ECYP1A2CYP2D6PDE4A | |
| SCHEMBL2628190 | 0.89 | SMN1; SMN2 (0.59) | KDM4ECYP1A2CYP2D6PDE4ASMN1; SMN2 | |
| SCHEMBL4275916 | 0.88 | LTA4H (0.52) | PLA2G4BKDM4ECYP1A2CYP2D6PDE4A | |
| SCHEMBL9140317 | 0.86 | PLA2G4B (0.62) | PLA2G4BKDM4ECYP1A2CYP2D6PDE4A | |
| SCHEMBL9476115 | 0.86 | PLA2G4B (0.62) | PLA2G4BKDM4ECYP1A2CYP2D6PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130065850-A1 | TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2013-03-14 | — | — | US | disclosed |
| US-8158677-B2 | Treatment of viral infections by modulation of host cell metabolic pathways | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2012-04-17 | — | — | US | disclosed |
| US-20090239830-A1 | Treatment of viral infections by modulation of host cell metabolic pathways | KADMON CORPORATION, LLC | 2009-09-24 | — | — | US | disclosed |
| WO-2009023059-A2 | TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239830-A1 | Treatment of viral infections by modulation of host cell metabolic pathways | GOT2, MAVS, ME3 | PLA2G4B 3710/4885KDM4E 2299/4885CYP1A2 559/4885 |
| US-20130065850-A1 | TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS | GOT2, MAVS, ME3 | PLA2G4B 3710/4885KDM4E 2299/4885CYP1A2 559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.